Aligos Therapeutics (ALGS) Assets (2019 - 2026)
Aligos Therapeutics' (ALGS) quarterly Assets came in at $64.6 million in Q1 2026, down 57.16% YoY from $150.7 million in Q1 2025, and down 27.08% on a QoQ basis from $88.5 million in Q4 2025.
Aligos Therapeutics (ALGS) Assets (2019 - 2026) Analysis & Trends
Aligos Therapeutics (ALGS) has 8 years of Assets data on file, last reported at $64.6 million in Q1 2026.
- Quarterly Assets fell 57.16% year-over-year to $64.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $64.6 million (down 57.16% YoY) and the FY2025 annual result came in at $88.5 million, up 26.31% from the prior year.
- Assets fell to $64.6 million in Q1 2026, from $88.5 million in the prior quarter.
- In the past five years, Assets ranged from a high of $210.5 million in Q1 2022 to a low of $64.6 million in Q1 2026.
- A 5-year average of $124.3 million and a median of $121.7 million in 2023 frame the typical range for Assets.
- Annual changes were most pronounced in 2025 — Assets climbed 26.31% — and 2026, when it slumped 57.16%.
- Tracing ALGS's Assets over 5 years: stood at $146.7 million in 2022, then increased by 3.3% to $151.5 million in 2023, then slumped by 53.74% to $70.1 million in 2024, then rose by 26.31% to $88.5 million in 2025, then dropped by 27.08% to $64.6 million in 2026.
- The last three Assets figures came in at $64.6 million (Q1 2026), $88.5 million (Q4 2025), and $109.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.56 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.10 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.60 Bn |
| 10 | Aligos Therapeutics | 67.38 Mn | 36.94 Mn | - | 66.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 66.33 Mn |
| Mar 31, 2026 | 64.56 Mn |
| Dec 31, 2025 | 88.53 Mn |
| Sep 30, 2025 | 109.76 Mn |
| Jun 30, 2025 | 134.71 Mn |
| Mar 31, 2025 | 150.70 Mn |
| Dec 31, 2024 | 70.09 Mn |
| Sep 30, 2024 | 88.43 Mn |
| Jun 30, 2024 | 108.81 Mn |
| Mar 31, 2024 | 127.90 Mn |
| Dec 31, 2023 | 151.53 Mn |
| Sep 30, 2023 | 85.85 Mn |
| Jun 30, 2023 | 106.13 Mn |
| Mar 31, 2023 | 121.74 Mn |
| Dec 31, 2022 | 146.69 Mn |
| Sep 30, 2022 | 164.07 Mn |
| Jun 30, 2022 | 182.52 Mn |
| Mar 31, 2022 | 210.47 Mn |
| Dec 31, 2021 | 235.37 Mn |
| Sep 30, 2021 | 263.07 Mn |